Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Pomalidomide in Relapsed/Refractory PCNSL and PVRL
NCT03798314Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pomalidomide in primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL), sponsored by Mayo Clinic. Primary endpoints: Maximum-tolerated dose of pomalidomide at 28 days, Incidence of adverse events at 12 weeks and 1 more. Started Jan 2019; status: completed.
02
Drugs
pomalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)primary vitreoretinal lymphoma (PVRL)
Beyond the preview
Go deeper on NCT03798314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798314.